

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Volume 35

October 1991

No. 10

MINIREVIEWS

- Antibiotic Tissue Penetration and Its Relevance: Models of Tissue Penetration and Their Meaning.** David E. Nix, S. Diane Goodwin, Charles A. Peloquin, Denise L. Rotella, and Jerome J. Schentag 1947–1952
- Antibiotic Tissue Penetration and Its Relevance: Impact of Tissue Penetration on Infection Response.** David E. Nix, S. Diane Goodwin, Charles A. Peloquin, Denise L. Rotella, and Jerome J. Schentag 1953–1959

MECHANISMS OF ACTION: PHYSIOLOGICAL EFFECTS

- Differential Modulation of Cytokine Production by Macrolides: Interleukin-6 Production Is Increased by Spiramycin and Erythromycin.** Sabine Bailly, Jean-Jacques Pocardalo, Michele Fay, and Marie-Anne Gougerot-Pocidalo 2016–2019
- Role of Protein D2 and Lipopolysaccharide in Diffusion of Quinolones through the Outer Membrane of *Pseudomonas aeruginosa*.** Mehri Michéa-Hamzehpour, Yves Xavier Furet, and Jean-Claude Pechère 2091–2097
- Aminoglycosides Modify the In Vitro Metachromatic Reaction and Murine Generalized Shwartzman Phenomenon Induced by *Salmonella minnesota* R595 Lipopolysaccharide.** A. Focà, G. Matera, D. Iannello, M. C. Berlinghieri, and M. C. Liberto 2161–2164

MECHANISMS OF RESISTANCE

- Borderline Susceptibility to Antistaphylococcal Penicillins Is Not Conferred Exclusively by the Hyperproduction of β -Lactamase.** Neil Barg, Henry Chambers, and Douglas Kernodle 1975–1979
- Characterization of Erythromycin Resistance in *Campylobacter jejuni* and *Campylobacter coli*.** William Yan and Diane E. Taylor 1989–1996
- A DNA Sequence Upstream of the *tet(O)* Gene Is Required for Full Expression of Tetracycline Resistance.** Ying Wang and Diane E. Taylor 2020–2025
- Use of a Broad-Host-Range *gyrA* Plasmid for Genetic Characterization of Fluoroquinolone-Resistant Gram-Negative Bacteria.** Peter Heisig and Bernd Wiedemann 2031–2036
- Emergence of Fluoroquinolone Resistance in *Campylobacter jejuni* and *Campylobacter coli* in Subjects from Finland.** Hilpi Rautelin, Olli-Veikko Renkonen, and Timo U. Kosunen 2065–2069
- Ciprofloxacin Resistance in Coagulase-Positive and -Negative Staphylococci: Role of Mutations at Serine 84 in the DNA Gyrase A Protein of *Staphylococcus aureus* and *Staphylococcus epidermidis*.** Santha Sreedharan, Lance R. Peterson, and L. Mark Fisher 2151–2154
- Increased Resistance to Multiple Drugs by Introduction of the *Enterobacter cloacae romA* Gene into OmpF Porin-Deficient Mutants of *Escherichia coli* K-12.** Takayuki Komatsu, Michio Ohta, Nobuo Kido, Yoshichika Arakawa, Hideo Ito, and Nobuo Kato 2155–2158

Continued on following page

SUSCEPTIBILITY

- In Vitro Activity of Orally Administered Antimicrobial Agents against *Haemophilus influenzae* Recovered from Children Monitored Longitudinally in a Group Day-Care Center.** Mary J. George, Barry Kitch, Frederick W. Henderson, and Peter H. Gilligan..... 1960–1964
- Chlorhexidine Resistance in Methicillin-Resistant *Staphylococcus aureus* or Just an Elevated MIC? An In Vitro and In Vivo Assessment.** B. D. Cookson, M. C. Bolton, and J. H. Platt 1997–2002
- Novel Method for Measuring Growth of *Treponema hyodysenteriae* and Its Application for Monitoring Susceptibility of Clinical Isolates to Antimicrobial Agents.** Frederick H. Weber and Daniel L. Earley 2012–2015
- Influence of Albumin on Itraconazole and Ketoconazole Antifungal Activity: Results of a Dynamic In Vitro Study.** Monika Schäfer-Korting, Hans Christian Korting, Franz Amann, Rudolf Peuser, and Andreas Lukacs..... 2053–2056
- Shell-Vial Assay: Evaluation of a New Technique for Determining Antibiotic Susceptibility, Tested in 13 Isolates of *Coxiella burnetii*.** D. Raoult, H. Torres, and M. Drancourt 2070–2077
- Bacterial and Fungal Killing by Iontophoresis with Long-Lived Electrodes.** C. P. Davis, N. Wagle, M. D. Anderson, and M. M. Warren 2131–2134
- Susceptibility of *Staphylococcus* Species and Subspecies to Fleroxacin.** Tammy L. Bannerman, Diane L. Wadiak, and Wesley E. Kloos..... 2135–2139
- In Vitro Activity of 79 Antimicrobial Agents against *Corynebacterium* Group D2.** J. A. García-Rodríguez, J. E. García Sánchez, J. L. Muñoz Bellido, T. Nebreda Mayoral, E. García Sánchez, and I. García García 2140–2143

BIOLOGIC RESPONSE MODIFIERS

- Effect of Dexamethasone or HWA-138 in Combination with Antibiotics in Experimental *Haemophilus influenzae* Type b Infection.** Adib F. Rodriguez, Sheldon L. Kaplan, Edith P. Hawkins, and Edward O. Mason, Jr. 1980–1984

ANTIVIRAL AGENTS

- Synergistic Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro by Two-Drug and Three-Drug Combinations of 3'-Azido-3'-Deoxythymidine, Phosphonoformate, and 2',3'-Dideoxythymidine.** Xiang-Bin Kong, Qing-Yu Zhu, Ruth M. Ruprecht, Kyoichi A. Watanabe, Joanna M. Zeidler, Jonathan W. M. Gold, Bruce Polsky, Donald Armstrong, and Ting-Chao Chou 2003–2011
- Selective Anabolism of 6-Methoxypurine Arabinoside in Varicella-Zoster Virus-Infected Cells.** Karen K. Biron, Paulo de Miranda, Thimysta C. Burnette, and Thomas A. Krenitsky 2116–2120
- Anabolic Pathway of 6-Methoxypurine Arabinoside in Cells Infected with Varicella-Zoster Virus.** Paulo de Miranda, Thimysta C. Burnette, Karen K. Biron, Richard L. Miller, Devron R. Averett, and Thomas A. Krenitsky 2121–2124
- Hygromycin B Therapy of a Murine Coronaviral Hepatitis.** Georgina Macintyre, Bernadette Curry, Fred Wong, and Robert Anderson..... 2125–2127
- Evaluation of Antiviral Activity and Toxicity of Dextran Sulfate in Feline Leukemia Virus-Infected Cats.** Lawrence E. Mathes, Kathleen A. Hayes, Cheryl L. Swenson, Phyllis J. Polas, Steven E. Weisbrode, and Gary J. Kociba 2147–2150

EXPERIMENTAL THERAPEUTICS

| | |
|--|-----------|
| Microculture Screening Assay for Primary In Vitro Evaluation of Drugs against <i>Pneumocystis carinii</i>. John C. W. Comley, Robert J. Mullin, Lawrence A. Wolfe, Mary H. Hanlon, and Robert Ferone | 1965–1974 |
| Efficacy of SCH 39304 in Treatment of Experimental Invasive Aspergillosis. Thomas F. Patterson, David George, Roxann Ingersoll, Peggy Minitier, and Vincent T. Andriole | 1985–1988 |
| In Vivo Activities of Newer Rifamycin Analogs against <i>Mycobacterium avium</i> Infection. S. P. Klemens and M. H. Cynamon | 2026–2030 |
| Use of Ampicillin-Sulbactam for Treatment of Experimental Meningitis Caused by a β-Lactamase-Producing Strain of <i>Escherichia coli</i> K-1. Luis Guerra-Romero, Stephen L. Kennedy, Michael A. Fournier, Jay H. Tureen, and Martin G. Täuber | 2037–2041 |
| Antifungal Activity of HWA-138 and Amphotericin B in Experimental Systemic Candidiasis. Kishor M. Wasan, Kiumars Vadiee, David R. Luke, Afsaneh Keyhani, R. Allen White, Teresa J. McQueen, Reeta Mehta, and Gabriel Lopez-Berestein | 2046–2048 |
| Treatment of Murine Invasive Candidiasis with Amphotericin B and Cilofungin: Evidence for Enhanced Activity with Combination Therapy. Alan M. Sugar, Luciano Z. Goldani, and Michele Picard | 2128–2130 |
| Comparative Efficacies of Amphotericin B Lipid Complex and Amphotericin B Deoxycholate Suspension against Murine Blastomycosis. Karl V. Clemons and David A. Stevens | 2144–2146 |

CLINICAL THERAPEUTICS

| | |
|--|-----------|
| Pyrimethamine-Clarithromycin Combination for Therapy of Acute <i>Toxoplasma</i> Encephalitis in Patients with AIDS. Julian Fernandez-Martin, Catherine Leport, Philippe Morlat, Marie-Caroline Meyohas, Jean-Pierre Chauvin, and Jean-Louis Vilde | 2049–2052 |
|--|-----------|

PHARMACOLOGY

| | |
|--|-----------|
| Pharmacokinetics of Cefuroxime Axetil Suspension in Infants and Children. Dwight A. Powell, Nancy C. James, Michael J. Ossi, Milap C. Nahata, and Karl H. Donn | 2042–2045 |
| Comparative Study of Pharmacokinetics and Serum Bactericidal Activity of Ceftizoxime and Cefotaxime. François Vallée and Marc LeBel | 2057–2064 |
| Single-Dose Pharmacokinetics of Ceftibuten (SCH 39720) in Infants and Children. Gregory L. Kearns, Michael D. Reed, Richard F. Jacobs, M. Ardite, Ram D. Yogev, and Jeffrey L. Blumer | 2078–2084 |
| Single Daily Dosing of Antibiotics: Importance of In Vitro Killing Rate, Serum Half-Life, and Protein Binding. Gilles Potel, Nguyen P. Chau, Béatrice Pangon, Bruno Fantin, Jean-Marie Vallois, François Faurisson, and Claude Carbon | 2085–2090 |
| Pharmacokinetics of Ampicillin-Sulbactam in Healthy Elderly and Young Volunteers. Burt R. Meyers, Patricia Wilkinson, Meryl H. Mendelson, Susan Walsh, Cynthia Bournazos, and Shalom Z. Hirschman | 2098–2101 |
| Effects of Two Cations on Gastrointestinal Absorption of Ofloxacin. M. Martínez Cabarga, A. Sánchez Navarro, C. I. Colino Gandarillas, and A. Domínguez-Gil | 2102–2105 |

Continued from preceding page

| | |
|--|-----------|
| Enantioselective Disposition of Ofloxacin in Humans. Osamu Okazaki, Chieko Kojima, Hideo Hokusui, and Mitsuyoshi Nakashima..... | 2106–2109 |
| Studies of Interaction of a Low-Molecular-Weight Heparinoid (Org 10172) with Cloxacillin and Ticarcillin in Healthy Male Volunteers. A. de Boer, J. C. J. Stiekema, M. Danhof, T. G. van Dinther, J. K. Boeijinga, A. F. Cohen, and D. D. Breimer | 2110–2115 |
| Ofloxacin Penetration into Tuberculous Pleural Effusion. Wing Wai Yew, Joseph Lee, Chiu Yeung Chan, Siu Wai Cheung, Poon Chuen Wong, and Susan Yuk Lin Kwan | 2159–2160 |

ERRATUM

| | |
|---|------|
| Bacterial Resistance to Macrolide, Lincosamide, and Streptogramin Antibiotics by Target Modification. Roland Leclercq and Patrice Courvalin..... | 2165 |
|---|------|